DiscoverClyde & Co | Insurance & Reinsurance UKEmerging Risk | Semaglutides: weighing up the risks
Emerging Risk | Semaglutides: weighing up the risks

Emerging Risk | Semaglutides: weighing up the risks

Update: 2025-04-22
Share

Description

The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.
Comments 
In Channel
Emerging Risk | Vaping

Emerging Risk | Vaping

2024-05-1033:29

loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Emerging Risk | Semaglutides: weighing up the risks

Emerging Risk | Semaglutides: weighing up the risks

Clyde & Co